COMMUNIQUÉS West-GlobeNewswire

-
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
15/10/2018 -
athenahealth Announces Third Quarter 2018 Earnings Conference Call
15/10/2018 -
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
15/10/2018 -
Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th
15/10/2018 -
PetMed Express D/B/A 1-800-PetMeds to Announce its Second Quarter Financial Results on October 22, 2018
15/10/2018 -
Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study
15/10/2018 -
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
15/10/2018 -
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
15/10/2018 -
Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer
15/10/2018 -
Avalon GloboCare Announces Grand Opening of Newly Renovated Headquarters in New Jersey
15/10/2018 -
Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
15/10/2018 -
Extendicare Announces October 2018 Dividend of C$0.04 per Share
15/10/2018 -
IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors
15/10/2018 -
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
15/10/2018 -
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
15/10/2018 -
CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™
15/10/2018 -
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15/10/2018 -
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
15/10/2018 -
GUERBET : Information sur les opération effectuées dans le cadre du programme de rachat d'actions
15/10/2018
Pages